{"entity":{"id":"nct07334119","kind":"trial","name":"Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT-304 in Adults With Advanced HER2-Expressing Solid Tumors","aka":[],"tldr":"A phase 1 trial of MT-304 run by Myeloid Therapeutics, now recruiting.","summary":"Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT-304 in Adults With Advanced HER2-Expressing Solid Tumors is a phase 1 interventional study registered as NCT07334119 by Myeloid Therapeutics, with 60 participants planned, started 2025-11-25, primary completion expected 2027-01-31. Conditions recorded: HER2-Expressing Solid Tumors. Interventions recorded: MT-304, MT-304 + Nivolumab.","status":"recruiting","asOf":"2026-11-04","links":[{"label":"ClinicalTrials.gov NCT07334119","url":"https://clinicaltrials.gov/study/NCT07334119"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["mt-304"],"companies":["create-medicines"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07334119","phase":"1","setting":"A Phase 1, Open-Label, First-in-Human, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT-304 in Adults With Advanced HER2-Expressing Solid Tumors","sponsor":"Myeloid Therapeutics","enrolled":60,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07334119/","neighbours":{"drug":[{"id":"mt-304","kind":"drug","name":"MT-304","route":"/drugs/mt-304/"}],"company":[{"id":"create-medicines","kind":"company","name":"CREATE Medicines","route":"/companies/create-medicines/"}]}}